Monthly summary - August 2024

SUMMARY

August started with a spike in volatility. Despite the initial stress, stock markets increased during the month, with the world index up 2.5 percent, measured in US dollars. Several central banks have now signalled their intention to cut interest rates in the coming months. The US election campaign is in full swing with continued even poll numbers. Healthcare and consumer goods showed the strongest development during the month and seemed to be the least affected by the dissolution of the carry trade.

MONTHLY COMMENT

The beginning of the month was characterized by a sharp spike in volatility due to the unwinding of the yen carry trade. This had a significant impact on currency trading, affecting the US dollar in particular, and contributed to increased volatility across multiple financial markets. Despite this, the stock market saw a gain in August with the world index up 2.5 percent, measured in US dollars.

Central banks ready to ease

Key central banks, including the Federal Reserve (Fed), the European Central Bank (ECB) and the Bank of England (BOE) signaled their intentions to lower interest rates in the coming months. This marked a clear shift from the recent period of higher borrowing costs. During the Jackson Hole symposium, Fed chair Jerome Powell indicated a pivot in monetary policy, hinting at a rate cut in September, stating that “the time has come for policy to adjust.” Powell emphasized that Fed policymakers were committed to supporting a strong labor market as inflation subsided. Overall, the market’s interpretation was that the Fed saw the need for a lower interest rate environment, in line both with declining inflation and signs of a weakening labor market.

The latest macroeconomic data of the month showed core PCE undershooting the Feds expectations for the third consecutive month, suggesting the possibility of downward revisions of future inflation forecasts. However, mixed signals persisted, with consumer spending and income growth remaining somewhat stronger than recent trends. Meanwhile, the savings rate dropped to 2.8 percent, the second lowest rate since 2008. This gave economists cause for concern that demand might decrease going forward, since they interpreted from the figures that the most financially vulnerable households were under increasing stress.

Olympic Games’ boost?

Inflation in the Eurozone fell to its lowest level in three years in August, bolstering the likelihood of further interest rate cuts by the ECB in September. This decline was mainly driven by lower energy prices, which brought inflation closer to the ECB’s target of two percent. However, the service component saw an uptick, likely due to higher spending during the Olympic Games in Paris. The market revised its expectations to six interest rate cuts before the end of next year, one more than projected in the ECB’s own forecasts.

Harris vs. Trump

During the Democratic National Convention in August, Kamala Harris was officially accepted as the party’s nominee. Harris saw a significant financial boost, raising more funds than her opponent, former president Donald Trump. Polls showed Harris slightly ahead, although the race remained close, particularly in key battleground states.

Polls for the US Senate and the House of Representatives was also difficult to predict and showed thin margins.

Strong month

With the exception of energy, all sectors rose during the month, measured in US dollars. Healthcare and consumer staples saw the strongest performances, as they were the least impacted by the carry trade unwind. Following the earnings season, many sectors exceeded expectations in both sales and earnings, which was an important factor behind the month’s overall gains.

REFLECTIONS FROM THE MANAGERS

As we hoped, August turned out to be a good month for the healthcare sector. The weaker dollar resulting from macro data in late July and August increasingly strengthened the thesis that we are finally reaching the point for the first US interest rate cut (September 18). The market recovered from fears of weaker growth related to the carry trade debacle at the beginning of the month, and moved quickly back to continued good ”risk/reward.”

Smaller companies slowly approaching the spotlight

Right now, it is relatively easy to be optimistic. The healthcare sector has delivered good reports and we note an encouraging stock market response. Overall markets have shown strength in August, a summer month that, historically, often tends to be weak. Interest rate cuts are now expected in many parts of the world. Inflation continues to decline, albeit at a slow pace. Many macro indicators also suggest that, hopefully, a recession in the US can be avoided, although this is still surrounded by uncertainty. Smaller companies are gradually becoming the focus of investor interest, although this is still at an early stage.

In line with how stock markets have often developed historically in presidential election years, we believe they could see a strong second half of the year. However, the period could deliver some surprises. Regardless of how political statements and proposals are perceived by market participants, the weeks ahead of an election is usually characterized by high volatility. A so-called ”sweep”, however, where one of the parties wins the presidency and both chambers of Congress, would probably complicate the stock market’s outlook on the economy and the perceptions of political risks likely to dominate the new administration. Shared power in Washington is often the foundation for political compromises, which in turn is often favorable for the stock market, even if compromises take time to work out. The economic cycle in Europe seems to be bottoming out at this point, but so far, the turnaround has not gained much momentum. Patience here is definitely needed.

 

Andra nyheter från oss

All

Direkt

Finwire

Uncategorized

Rhenman & Partners

Monthly comment (Apr 25): Healthcare sector impacted by political uncertainty

Monthly summary – March 2025: a volatile month, again impacted by the macro-economic and political backdrop

Rhenman Healthcare Equity L/S minskade 13,61 procent i mars – volatilt för hälsovårdssektorn

Monthly summary – February 2025: Sentiment turned sour in February

Rhenman Healthcare Equity L/S sjönk 4,52 procent i februari – politisk osäkerhet pressade marknaden

Rhenman & Partners strengthens its Operations Team

Rhenman & Partners förstärker sitt Operationsteam

Monthly comment – January 2025: All sectors except technology closing in positive territory

Rhenman Healthcare Equity L/S ökade 8,41 procent i januari – stark rotation mot hälsovård

Monthly comment – December 2024

Rhenman Healthcare Equity L/S minskade 10,48 procent i december – tungt avslut på 2024

Monthly summary – November 2024: Once the election results were in, focus shifted torwards likely economic implications

Rhenman Healthcare Equity L/S ökade 1,67 procent i november – volatilt efter valet i USA

How is the healthcare sector affected by the US election results?

Hur påverkas en av världens mest reglerade sektorer av valutgången i USA?

Rhenman Healthcare Equity L/S minskade 2,00 procent i oktober – fokus på rapportperiod och USA-val

October 2024 summary – Initital focus on the earnings season switched to focus on election outcomes

Rhenman Healthcare Equity L/S föll 3,53 procent i september – positiv långsiktig utsikt trots volatil marknad

Monthly summary – September 2024

Rhenman & Partners strengthens its Investor Relations team further

Rhenman & Partners förstärker sitt Investor Relations-team ytterligare

Rhenman Healthcare Equity L/S ökade 3,35 procent i augusti – optimistisk syn på andra halvåret

Rhenman & Partners förstärker investeringsteamet – ytterligare en portföljförvaltare inom biopharma

Rhenman & Partners strengthens investment team – hires additional biopharma PM

Rhenman Healthcare Equity L/S ökade 5,26 procent i juli – tydlig sektorrotation

Monthly update – July 2024

Rhenman Healthcare Equity L/S ökade 1,42 procent i juni – stark månad för aktiemarknaden

Monthly summary – June 2024

Rhenman & Partners celebrates 15 years

Rhenman Healthcare Equity L/S föll 1,29 procent i maj – ser positivt på andra halvåret

Monthly summary – May 2024

Rhenman Healthcare Equity L/S minskade 2,57 procent i april – svag utveckling för de flesta delsektorer

Monthly summary – April

Rhenman Healthcare Equity L/S ökade 5,86 procent i mars – starka bidrag från medicinteknik

Monthly summary – March 2024

Rhenman & Partners strengthens its investor relations team

Rhenman & Partners förstärker Investor Relations

Rhenman Healthcare Equity L/S ökade 4,45 procent i februari – stark månad för bioteknik

Monthly summary – February 2024

Rhenman Healthcare Equity ökade 6,17 procent i januari – Shockwave och Eli Lilly bidrog positivt

Monthly summary – January 2024

Monthly summary – December 2023

Rhenman Healthcare Equity L/S ökade 5,43 procent i december – Cytokinetics bidrog positivt till utvecklingen

Monthly summary – November 2023

Monthly update – November 2023

Rhenman Healthcare Equity ökade 3,58 procent i november – Immunogen bidrog positivt

Monthly summary – October

Rhenman Healthcare Equity minskade 3,03 procent i oktober – två uppköp under månaden

The complex reality of investing in Biopharma

Rhenman Healthcare Equity minskade 6,07 procent i september – Immunovant steg kraftigt efter goda resultat

Monthly summary – September

Rhenman Healthcare Equity ökade 2,91 procent i augusti – Eli Lilly och Novo Nordisk i blickfånget

MONTHLY SUMMARY – AUGUST 2023

Rhenman Healthcare Equity minskade 4,01 procent i juli – Apellis Pharmaceuticals tyngde utvecklingen

Rhenman Healthcare Equity L/S ökade 2,65 procent i juni – ökar allokeringen mot tryggare bolag

Monthly summary – June 2023

Susanna Urdmark lämnar Rhenman & Partners

Susanna Urdmark to leave Rhenman & Partners

Susanna Urdmark lämnar Rhenman & Partners

Rhenman Healthcare Equity ökade 3,24 procent i maj – Immunogen bidrog positivt till utvecklingen

Dan Hoflund ny styrelseledamot för Rhenman & Partners Asset Management

Rhenman Healthcare Equity L/S ökade 3,83 procent i april – Tenet Health utvecklades starkt

Monthly summary – April 2023

Rhenman Healthcare Equity L/S minskade 1,02 procent i mars – Novo Nordisk aktiekurs fortsätter stiga

Monthly summary – March 2023

Lars Wedenborn ny styrelseledamot för Rhenman & Partners Asset Management

Lars Wedenborn – ny styrelseledamot Rhenman & Partners Asset Management

Rhenman Healthcare Equity L/S minskade 4,42 procent i februari – rekyl på aktiemarknaderna under februari

Monthly summary – February 2023

Rhenman Healthcare Equity ökade 3,75 procent i januari – Revance Therapeutics och Tenet Healthcare bidrog positivt (uppdatering)

Rhenman Healthcare Equity ökade 3,75 procent i januari – Revance Therapeutics och Tenet Healthcare bidrog positivt

Monthly summary – January 2023

Rhenman Healthcare Equity minskade 4,76 procent i december – Horizon Therapeutics främsta bidragsgivare

Monthly summary – December 2022

Rhenman & Partners strengthens its investment team with a biopharma analyst

Rhenman & Partners förstärker sitt investeringsteam med biopharmananlytiker

Rhenman Healthcare Equity L/S ökade 2,51 procent i november – Abiomed och Horizon Health bidrog positivt

Summary – November 2022

Rhenman Healthcare Equity L/S: +5,7% i oktober, flera faktorer pekar på hyfsad vinter men makrorisker ska ej underskattas – förvaltare

Summary – October 2022

Rhenman Healthcare Equity L/S ökade 5,68 procent i oktober – lyfter fram potentiell presidentcykeleffekt

Rhenman Healthcare Equity L/S: -1,5% i september, investmentbanker sänkte Jazz Pharmaceuticals och Vitrolife (R)

Rhenman Healthcare Equity L/S minskade 1,5 procent i september – Revance Therapeutics och Regeneron Pharmaceuticals främsta bidragsgivare

Teresa Isele ny vd för Rhenman & Partners Asset Management

Teresa Isele ny VD för Rhenman & Partners Asset Management AB

Teresa Isele to be the new CEO of Rhenman & Partners Asset Management AB

Rhenman Healthcare Equity L/S: +1,7% i augusti, förvaltare positiva till amerikansk läkemedelsreform

Rhenman Healthcare Equity L/S ökade 1,70 procent i augusti – biotekniksektorn gynnade utvecklingen

Rhenman Healthcare Equity L/S RC1 SEK: +5,4% i juli, ser på uppgångarna med försiktighet

Rhenman Healthcare Equity L/S ökade 5,39 procent i juli – fortsatt försiktig inställning

Rhenman Healthcare Equity L/S: +4,5% i juni, ser inte läge att öka aktieexponering trots viss ljusning.

Rhenman Healthcare Equity L/S ökade 4,50 procent i juni – stark återhämtning från små- och medelstora bioteknikbolag

Rhenman Healthcare Equity L/S minskade 3,19 procent i maj – stora läkemedelsbolag bidrog positivt

RHENMAN HEALTHCARE EQUITY L/S: -3,2% I MAJ, BUD PÅ BIOHAVEN

Rhenman & Partners fortsätter att expandera – sök rollen som biopharma-analytiker

Rhenman & Partners winner of Refinitiv Lipper Fund Awards Nordics

Rhenman & Partners vinnare av internationellt fondpris

Lediga tjänster inom Investor Relations

Rhenman Healthcare Equity L/S: -4,9% i april, tyngdpunkt på stora bolag för tillfället

Rhenman Healthcare Equity L/S minskade 4,93 procent i april – läkemedelsbolag minst påverkade av ökad global osäkerhet

EN